This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- Efficacy and Safety of 124I-MIBG Dosimetry-Guided High-Activity 131I-MIBG Therapy of Advanced Pheochromocytoma or Neuroblastoma
- Diagnostic Performance of 124I-Metaiodobenzylguanidine PET/CT in Patients with Pheochromocytoma
- Imaging of Pheochromocytoma and Paraganglioma
- Semiquantitative mIBG Scoring as a Prognostic Indicator in Patients with Stage 4 Neuroblastoma: A Report from the Children's Oncology Group
- Treatment of a Malignant Pheochromocytoma in a Dog Using 131I Metaiodobenzylguanidine
- Usefulness of 123I-MIBG Scintigraphy in the Evaluation of Patients with Known or Suspected Primary or Metastatic Pheochromocytoma or Paraganglioma: Results from a Prospective Multicenter Trial
- Extended stability of iobenguane under simulated clinical conditions
- Acute intermittent porphyria and phaeochromocytoma: shared features
- A meta-iodobenzylguanidine scintigraphic scoring system increases accuracy in the diagnostic management of pheochromocytoma.
- Diagnosis and Localization of Pheochromocytoma
- False positive uptake of metaiodobenzylguanidine in hepatocellular carcinoma
- Pilot Study of Iodine-131-Metaiodobenzylguanidine in Combination With Myeloablative Chemotherapy and Autologous Stem-Cell Support for the Treatment of Neuroblastoma
- Functioning adrenal pathology